A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys
- 11 September 2006
- Vol. 40 (1) , 122-131
- https://doi.org/10.1016/j.bone.2006.07.015
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Bone safety of long-term bisphosphonate treatmentCurrent Medical Research and Opinion, 2004
- Cathepsin L‐deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomyInternational Journal of Experimental Pathology, 2004
- Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosisCurrent Medical Research and Opinion, 2004
- The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen DegradationJournal of Bone and Mineral Research, 2003
- Perspective: Reconsidering the Effects of Antiresorptive Therapies in Reducing Osteoporotic FractureJournal of Bone and Mineral Research, 2001
- Potent and Selective Cathepsin L Inhibitors Do Not Inhibit Human Osteoclast Resorption in VitroJournal of Biological Chemistry, 2001
- Development and Characterization of a Human In Vitro Resorption Assay: Demonstration of Utility Using Novel Antiresorptive AgentsJournal of Bone and Mineral Research, 1999
- Cathepsin K mRNA Detection Is Restricted to Osteoclasts During Fetal Mouse DevelopmentJournal of Bone and Mineral Research, 1998
- Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K DeficiencyScience, 1996
- Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human OsteoclastsJournal of Biological Chemistry, 1996